Introduction
Geriatric(orlate-life)depressionreferstodepressive syndromes that develop in people aged 65 yearsorolder. 1 Depressivesyndromescommonly affectolderpeoplewithchronicdisease,cognitive impairmentorotherformsofdisability. [2] [3] [4] [5] Depressionpromotesdisabilityinthispopulationandis associatedwithnegativeoutcomesofchronicdisease,suchasincreasedhealthcareutilizationand mortality. 2 Geriatricdepressionisoftenundetected orundertreatedinprimarycaresettingsforvariousreasons,includingthe(incorrect)beliefthat depressionisanormalpartofaging.Ithasbeen predictedbytheWorldHealthOrganizationthat by2020depressionwillbesecondonlytoheart disease as a cause of disability and premature death in developed countries. 6 The purpose of thisreviewistodiscussselectedissuesingeriatric depression,withafocusonpharmacotherapeutic considerations.
Diagnosis
DepressionisusuallydiagnosedusingtheAmeri-canPsychiatricAssociation'sDiagnostic and Statis-tical Manual of Mental Disorders,FourthEdition, Text Revision (DSM-IV-TR) criteria for major depressivedisorder. 1 Specifically,5ofthefollowing symptomsmustbepresent:diminishedinterest, lossofpleasureinalloralmostallactivities,weight lossorgain(>5%ofbodyweight),insomniaor hypersomnia,psychomotoragitationorretardation, fatigue, feelings of worthlessness or inappropriateguilt,reducedabilitytoconcentrateor recurrentthoughtsofdeathorsuicide.Thediagnosisofdepressionrequiresthateitherdepressed moodoranhedoniabepresent,thatthesyndrome last at least 2 weeks, that it lead to distress and functionalimpairmentandthatitnotbeadirect effectofsubstanceabuse,amedicalconditionor bereavement. While the DSM-IV-TR does not specifydifferentsymptomsordifferentdiagnostic criteriaforgeriatricdepression,itisimportantto notethatthediagnosisofdepressionintheolder populationcanbecomplicatedbyotherdisorders (seebelow)andalsobyitspresentation(Box1). For example, depressed mood (the hallmark of depression)tendstobeunder-reportedbyolder patientsandthusappearstobelessprevalentthan C L I N I C A L R E V I E W
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Carlos Rojas-Fernandez, BSc Late-life depression is common in older people. Its incidence increases significantly after age 70 to 85, as well as among those living in long-term care facilities. Depression contributes to excess morbidity and complicates management of comorbid conditions in older people. Diagnosis and management of depression often present clinicians with a challenge. Indeed, symptoms of depression in older people may not always be the same as those associated with depression in younger people. Additionally, age-related changes in pharmacokinetics and pharmacodynamics also impact selection, dosing, and monitoring of psychopharmacologic regimens. Optimizing management of depression and providing sound advice to older patients with depression requires knowledge and understanding of many clinical factors. The purpose of this review is to highlight salient issues in latelife depression, with a focus on the pharmacotherapy of depression. Can Pharm J 2012;145:128-135.e2. otherdepressivesymptomssuchasanergia(lack ofenergy),anhedonia,lossofappetiteorsleeplessness. 7, 8 Olderpatientsmayreportmoresomatic complaints (e.g., persistent unexplained pain, headache,fatigue,anorexia,gastrointestinalsymptomsandweightloss),anxietyorhypochondriasisratherthanreportingfeelingsadordepressed. Additionally, patients may present with apathy, withdrawal, lack of vigour (i.e., fatigue), psychomotorretardationandcognitiveimpairment ratherthanthe"usual"symptomsofdepression asdescribedabove. 5, [9] [10] [11] Inhospitalsettings,depressionshouldbesuspectedinpatientswhoexhibit poorrecovery,pooradherencewithrehabilitation programs,treatmentrefusal,functionaldeclineor increaseddependency.Depressionshouldalsobe suspectedinthosewhoarehighusersofhealth care services or those with persistent but unexplained weight loss, anorexia, pain, headache, fatigue,insomniaorgastrointestinalsymptoms.If thesesubtledifferencesareappreciated,itwillhelp ensureaproperdiagnosticworkup,whichisessential,asgeriatricdepressionisunder-recognizedin asmanyas50%ofpatients. 10 Screeningtoolssuch asthe9-itemPatientHealthQuestionnaire(PHQ-9)ortheGeriatricDepressionScale(GDS)maybe helpfulinthiscontext. 12, 13 Depressionmayalsopresentwithoverlapping symptomsofcomorbidmedicalillnesses(which arecommoninthisagegroup)andthusmustbe consideredwithinthiscontext.Forexample,itis not uncommon for older people to suffer from arthritis,coronaryheartdiseaseorheartfailure, whosesymptoms(e.g.,achesandpains,dyspnea, tiredness or fatigue, decreased appetite and/or weightloss,anxiety)overlapwithsomaticsymptoms of depression. 4, 7, [9] [10] [11] In this high-risk older population,physicalillnessesmustberuledout beforethepresentingsymptomsareattributedto depression.
Itshouldalsobenotedthatdepressioninolder people usually occurs against a background of medicaldisorders.Indeed,therearetimeswhen suchdisorders(e.g.,cardiovasculardiseaseleadingtoamyocardialinfarction)predisposeortriggerdepressioninvulnerableindividualsandithas beenshownthatthegreatertheindividual'soverallmedicalburden,thehighertheriskofdepression. 14, 15 Additionally,distinctivedepressivesyn-dromesarealsoobservedinthosewithAlzheimer disease, significant cerebrovascular disease and depression-executivedysfunctionsyndrome. [16] [17] [18] [19] [20] [21] 
Medications as potential contributors to depression
Medicationsareapotential,albeituncommon,iatrogeniccauseofdepressivesymptoms.Manydrugs havebeenimplicated,including,butnotlimitedto, antipsychotics,antiparkinsoniandrugs,benzodiazepines,cimetidine,digoxin,clonidine,hydralazine,dextropropoxyphene,methyldopa,propranolol,reserpine,steroids,progesterone,estrogens, vinblastine, vincristine and tamoxifen. 22 During the workup of a patient withsuspecteddepression, a complete medical and medication history and physical examination are indicated to assess conditions that may contribute to depression (e.g., hypothyroidism, alcohol, prescriptiondrugabuse). 4, 5, 23 
Epidemiology of depression and antidepressant use in older people
Approximately 1% to 4% ofthegeneralolderpopulation suffers from major depression; women are affectedatabouttwicetherateofmen. 9, 10, 24 Ofparticularrelevanceistheobservationthattheincidenceandprevalenceofdepressiondoubleafter theageof70-85years. 4 Inmedicalsettings,the prevalenceofmajordepressionincreasesmarkedly toabout12%forthoseadmittedtohospitaland 14%forthoseresidingin nursinghomes. 10 • In older people, symptoms of depression may be different than in younger patients, and often include memory and concentration problems, various vague somatic complaints, apathy, irritability and more. • Age-related changes in pharmacokinetics and pharmacodynamics have important implications in terms of selecting appropriate antidepressant medications.
• If treatment with the first antidepressant regimen is unsuccessful, options include switching medications or combining medications.
• This review provides practical information that pharmacists may use to better understand the appropriate treatment of depression in older people. 25 Similar findings have been reported by others, suggesting that much work remains to be done to improve the care of older depressed patients. 26, 27 On the positiveside,theseinvestigatorsnotedameaningful decreaseovertimeintheuseofpotentiallyhazardousantidepressantdrugs.Predictorsofantidepressantusehavealsobeenassessed. 25, 28 Forexample, somepredictorsofpotentiallyhazardousregimens haveincludedanageof65-74years,nursinghome residence,lesscomorbidity,morephysicianvisits andearlierstudyyears,whilepredictorsoflow-intensityregimensincludedage>85years,nonwhiterace,greatercomorbidity,fewerphysician visitsandnotusingotherpsychotropicmedications.Whileepidemiologicalstudieshavelimita-tions,theyneverthelessprovideusefulinformation that may be used for educational purposes and for planning future studies aimed at improving thepharmacotherapyofdepressionintheolder population.
Pharmacotherapy
Therearevarioustreatmentgoalsthatareimportant(e.g.,symptomreduction,preventingsuicidal ideation, preventing relapse, improving cognitiveandfunctionalstatus),butbroadlyspeaking, thereare2importantoverarchingconstructsthat shouldbekeptinmind:responseandremission (Box 2). [29] [30] [31] The differentiation is an important one;theultimategoaloftreatmentshouldalways beremission,aspatientswhorespondbutdonot achieve remission tend to have worse all-cause outcomescomparedtothoseinremission. 32 That said,itcanbechallengingtoobtainremissionin agivenpatient,asdemonstratedbytherecently published Sequenced Treatment Alternatives to RelieveDepression(STAR*D)study,inwhichonly about30%ofpatientsachievedremissionafterthe firstleveloftreatmentwithcitalopram(seebelow, Combining and augmenting antidepressants). 33 Manyantidepressantdrugsarecurrentlyavailableanditisgenerallyacceptedthattheydemonstratesimilarefficacyatthepopulationlevel; thus,theusualapproachistoselectadrugbased on its tolerability (Table 1) , potential for drug interactions(Tables2and3)andcost. [34] [35] [36] [37] [38] [39] [40] [41] Incontemporarypractice,selectiveserotoninreuptake inhibitors(SSRIs)areusedasfirst-lineagentsdue totheireaseofuse.ThemostsuitableSSRIsfor olderpeoplearesertraline,citalopramandescitalopram. 42, 43 Fluoxetineisnotconsideredagood choiceduetoitslonghalf-lifeandpropensityto causeexcessivestimulation,sleepdisturbanceand agitation, while paroxetine has mild, but clinicallyrelevant,anticholinergicproperties. 5,44 SSRIrelatedadverseeffectsofparticularimportancein theolderpopulationincludedyspepsiaornausea (whichusuallysubsidewithin7-10days),hyponatremia,anorexiaandweightloss.Clinicallyrelevantdrug-druginteractionsarefew;however,the riskofserotonintoxicityissignificantifSSRIsare combinedwithdrugsknowntoincreaseintrasynapticserotonin,suchasserotonin-norepinephrine reuptakeinhibitors(SNRIs),monoamineoxidase inhibitors (MAOIs) and others (e.g., meperidine, tramadol, some TCAs, linezolid). 45 Drugs thatinhibitthereuptakeofnorepinephrineand serotonin (e.g., venlafaxine, duloxetine) representusefulalternativesforpatientswithcoexistingpain,especiallyneuropathicpain. 46 Remission: Typically defined as a depression scale score below a pre-specified threshold that is consistent with a relative absence of depressive symptoms (i.e., euthymia) and lack of interest/pleasure and includes, at most, 2 other depressive symptoms. 44 Itisimportanttonotethatdosingof nortriptylineanddesipramine,unlikeotherantidepressants, needs to be guided by monitoring plasma concentrations, with target therapeutic rangesof60-120µg/Land>115µg/L,respectively. Lastly,MAOIsareaclassofantidepressantsthat arenotextensivelyusedinolderpeople,mostly due to the required dietary modifications and potentialfordrug-druginteractions. 49 Usingappropriatedosingstrategiesinorderto maximizethechanceofsuccessandminimizethe riskofsideeffectsisofparamountimportance. Specifically,lowerstartingdosesshouldbeused (seeTable1),yetfinaldosesshouldbeinthesame rangeasfortheadultpopulationtoincreasethe chanceofanadequateresponseandremission. 50, 51 If a patient is not adequately responding to an antidepressant, there are various options avail-able,suchasswitchingtoanotherantidepressant, combiningantidepressants,usingadjunctivepharmacologicaltreatmentsorelectroconvulsivetherapy. [52] [53] [54] Ifapatient'stherapyistobeswitched,akey considerationmayinvolvethegradualtaperingof theexistingantidepressantinordertoavoidwithdrawalsyndromeswithshorthalf-lifedrugs(e.g., paroxetine,venlafaxine)anddrugspossessingsignificantanticholinergicproperties. 50, 53 Thereare severaldifferentwaystodothis,includingusing a complete washout period (gradually tapering onebeforestartinganother-appropriatewhen switchingfromanirreversibleMAOItoanother antidepressant)orusingthecrossovertechnique (graduallyreducingthedoseof1drugwhileslowly starting the new agent). In all cases, individual patienttolerancemustbeconsidered.
Combining and augmenting antidepressants
Onlyabout40%to50%ofolderadultswithnonpsychoticmajordepressivedisorderwillrespond tothefirstprescribedantidepressantwithin2-3 months,makingitclearthatalternativestrategies arenecessaryformanypatients. 50, 51 Aspreviously noted,combinationsofdrugsareoftenrequired to increase response/remissions rates. There are 2 main objectives when considering combinationtherapy.Thefirstistoincreaseresponseor remission rates and the second is to reduce the rateofrelapseorrecurrence. 55 Whencombining antidepressants,itisimportanttocombineagents withdifferentmechanismsofaction,forexample, SSRIswithbupropion,SSRIswithselectedTCAs (desipramineornortriptyline)orSSRIswithmirtazapine. [55] [56] [57] [58] [59] [60] Augmentationstrategiesdifferfromcombinationtherapyinthattheyinvolvetheuseofmedica- n.B. The metabolism of most antidepressant drugs is at least partially dependent on hepatic microsomal cytochrome p450 isoenzymes. Any drug or natural health product that is a substrate, inducer or inhibitor of these CYp isoenzymes may also interact. * Risk of developing serotonin syndrome in combination with buspirone, linezolid, L-tryptophan, MAOIs, sibutramine, St. John's wort, tramadol, TCAs, triptans, SnRIs and SSRIs. † Risk of qTc prolongation in combination with dronedarone, nilotinib, pimozide, quinine, tetrabenazine, thioridazine and ziprasidone. qTc-prolonging agents include amiodarone, chlorpromazine, clarithromycin, domperidone, erythromycin, haloperidol, methadone, pimozide, quinidine, quinine, sotalol and ziprasidone. ‡ Mirtazapine dose may need to be increased when given concomitantly with phenytoin or carbamazepine. Monitor InR when concomitantly given with warfarin.
(cont.)
tionsthatarenottypicallyconsideredantidepressants(Box3)inordertoenhancethetherapeutic effect of a known antidepressant. 56 Along these lines, the STAR*D trial was the first large-scale study that examined the effectiveness of differenttreatmentstrategies,includingaugmentation withlithium,triiodothyronine(T 3 ),buspironeor bupropion,forpatientswhodidnotachieveremission after initial therapy with citalopram. This studyincludedapopulation(meanage40years, with741[25%]ofthesample>51years,withmedicalandpsychiatriccomorbidities)ofpatientswith majordepressivedisorderwhoinitiallyreceived citalopram and subsequently received up to 3 additionalstepsifremissionwasnotachievedor themedicationwasintolerable. 55 Thestudy'sprimaryoutcomemeasurewasremission,definedasa scoreof#7onthe17-itemHamiltonRatingScale for Depression. A key finding from the study was that lower remission rates were observed when multiple treatment steps were required. The observed remission rates were 37%, 31%, 14% and 13% following treatment steps 1 through 4, respectively (seeRushetal.foradetailedreview ofSTAR*Dresults). 56 Withregardto tolerability,significantlymorepatients takinglithiumexitedthestudydueto side effects compared to those taking T 3 (23% vs 9%, p < 0.05), while sustained-releasebupropionwasbetter tolerated, as demonstrated by a lowerrateofdiscontinuation(12.5%) compared with buspirone (20.6%). Some antipsychotics, specifically aripiprazole, olanzapineandquetiapine,havebeenwellstudiedasaugmentingagentsinpatientswithdepres-sionwhohavefailedtoremitwithmorethan1 priorantidepressanttrial. [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] Infact,intheUnited States,aripiprazoleandquetiapinearebothFDA approved for use as adjuncts to antidepressants forpatientswithunipolar,nonpsychoticdepression. 71, 72 Instudiesofthesedrugs,remissionrates havebeenconsistently(andsignificantly)higher whenantipsychoticsareusedasadjunctstoantidepressantsversusantidepressantsalone. 65, 70 Fora moredetaileddiscussion,thereaderisreferredtoa recentreviewandmeta-analysisofthisstrategy. 73, 74 Itisworthmentioningthattheaforementioned augmentation strategies are not well studied in older people. Nevertheless, this should not dissuadecliniciansfromusingselectedaugmentation strategies to help patients achieve remission. In general,medicationsthatarewelltoleratedinthis populationforthispurposeincludebupropion,T 3 , aripiprazoleandmirtazapine.
Time to response and treatment duration
Older patients may respond as well as younger patients, but may require longer for the full responsetobeobserved(i.e.,8-12weeksoftreatment). 50, 51 Interestingly,recentdatasuggestthat early improvement may be a good predictor of subsequentresponse.Forexample,Mulsantetal. foundthatafullresponsecanbeexpectedintwothirdsofpatientswhohavepartialimprovement after4weeksoftreatment. 75 Closemonitoringof thepatientisofparamountimportanceduringthe first8-10weeksoftreatment.Forexample,weekly orbiweeklycontactseitherinpersonorbytelephoneshouldoccurtomonitorforadverseeffects, druginteractions,worseningorimprovementof depressive symptoms and to further adjust the regimenifnecessary.Monitoringcanbeimproved byusingratingscalessuchasthePHQ-9,withthe goalbeingremission(i.e.,PHQ-9score<5).Minor depressionanddysthymiamayexhibitagreater and faster improvement in symptoms when treatedwithpharmacotherapycomparedtoplacebo,althoughremissionratesarenotsignificantly different. 76 An adequate duration of treatment is a key factor for successful long-term management of depression.Intheabsenceoflong-termtreatment, highratesofrelapseandrecurrenceareobserved. 77 Inarecentstudyofcommunity-dwellingelderly peoplewithmajordepression,approximately60% becamedepressedagainwithin2yearsunlessthey were maintained on antidepressant therapy. 78 Similarly, a study on maintenance therapies in recurrent depression found that even when an antidepressantwasprescribedforatleast3years 
Pharmacist's role and conclusions
Pharmacistscanplayasignificantroleindepressionmanagementastheyarereadilyaccessibleto patientsandareabletomaintaintrustingrelation-ships. 82 • provide patients with self-rating scales (e.g., 9-item patient Health questionnaire, the geriatric Depression Scale, the Cornell Scale for Depression in Dementia) to aid in monitoring progress. • Stress the importance of adherence to antidepressants. • provide a call-back service to patients to assess their progress.
• provide support to the patient and their caregiver.
